Stifel Nicolaus Initiates Coverage on Avalo Therapeutics (NASDAQ:AVTX)

Stifel Nicolaus started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report issued on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $36.00 price objective on the stock.

AVTX has been the subject of several other research reports. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective for the company. BTIG Research assumed coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Trading Up 11.9 %

NASDAQ AVTX opened at $8.54 on Tuesday. The business’s 50 day moving average is $7.51 and its two-hundred day moving average is $9.14. Avalo Therapeutics has a 12-month low of $4.60 and a 12-month high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BVF Inc. IL raised its position in shares of Avalo Therapeutics by 7.2% during the 4th quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock worth $7,703,000 after purchasing an additional 69,679 shares during the last quarter. Ikarian Capital LLC increased its position in Avalo Therapeutics by 1,673.0% during the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after buying an additional 915,629 shares in the last quarter. RA Capital Management L.P. acquired a new position in shares of Avalo Therapeutics in the third quarter worth $9,186,000. Affinity Asset Advisors LLC lifted its position in shares of Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after acquiring an additional 505,765 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Avalo Therapeutics during the fourth quarter valued at $817,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.